Manju T. Beier, PharmD, CGP, FASCP
Senior Partner, Geriatric Consultant Resources LLC
Clinical Associate Professor
College of Pharmacy
The University of Michigan
Ann Arbor, MI
David S. Geldmacher, MD, FACP
Harrison Distinguished Teaching Associate Professor
Department of Neurology
University of Virginia School of Medicine
Pharmacists: 1.25 Contact Hours (0.125 CEUs)
NOTE: This activity was presented on November 10, 2010, in conjunction with ASCP's Annual Meeting and Exhibition.
Participants who received credit for attending either the live presentation or the webcast on that date are not eligible to receive credit for this online activity.
The burden of Alzheimer's disease (AD), the most common form of dementia, is well known. It is now the sixth leading cause of death in Americans over the age of 65. More than 5 million individuals in the US have a diagnosis of AD—a number that is expected to climb to 7.7 million people by the year 2030. Although current therapies cannot cure or stop the progression of Alzheimer's disease, FDA-approved drugs may temporarily delay worsening of symptoms, preserve cognitive function, and help control behavioral symptoms, thereby improving the quality of life for patients and their caregivers.
Consultant and senior care pharmacists play a critical role in ensuring that patients are evaluated, monitored and treated appropriately. Patients with dementia need to be stratified based on their severity of disease and treated accordingly, but many healthcare professionals do not know how long to treat AD since there is no established standard on the duration of treatment. Furthermore, managing multiple medications can be especially challenging due to side effects and drug interactions. This activity will review evidence-based treatment and management goals for AD, and focus on tangible ways to improve patient care by improving recognition, diagnosis, and individualization of treatment for each patient. A brief discussion on new modalities of treatment and future directions for AD research will be presented.
This educational activity is designed to meet the needs of consultant and senior care pharmacists.
Upon completion of this knowledge-based educational activity, the participant should be able to:
Identify ways to improve the evaluation of patients who may have early Alzheimer’s disease.
Develop tailored Alzheimer’s disease treatment plans for patients who have varying degrees of disease severity.
Describe methods to manage common side effects associated with cholinesterase inhibitor and NMDA receptor antagonist monotherapy and combination therapy.
Outline comprehensive treatment care plans for Alzheimer’s disease to manage behavior and decrease the use of psychotropic drugs.
In accordance with the standards set forth by the Accreditation Council for Pharmacy Education, it is the policy of the American Society of Consultant Pharmacists to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Beier discloses that she has served as a consultant for Novartis Pharmaceuticals and on speakers’ bureaus for Eisai Pharmaceuticals and Novartis Pharmaceuticals.
Dr. Geldmacher discloses that he has served as a consultant for Janssen and as a clinical investigator for Eisai Pharmaceuticals, Forest Pharmaceuticals, Inc., Janssen, Novartis, and Pfizer Inc.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity, ACPE Universal Activity #203-999-10-114-H01-P, has been assigned 1.25 Contact Hours (0.125 CEUs).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.
Partial credit cannot be awarded.
There is no fee to participate in this educational activity. Commercial Support Statements
This activity is supported through educational grants from Forest Laboratories, Inc. and Eisai Pharmaceuticals. Instructions
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7. Or, Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The activity will take approximately 60 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.